PLUS THERAPEUTICS INC (PSTV) Stock Fundamental Analysis
USA - NASDAQ:PSTV - US72941H5090 - Common Stock
0.5115 USD
-0.01 (-1.2%)
We assign a fundamental rating of 2 out of 10 to PSTV. PSTV was compared to 534 industry peers in the Biotechnology industry. PSTV scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PSTV is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year PSTV has reported negative net income.
In the past year PSTV has reported a negative cash flow from operations.
In the past 5 years PSTV always reported negative net income.
PSTV had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PSTV's Return On Assets of -183.84% is on the low side compared to the rest of the industry. PSTV is outperformed by 88.76% of its industry peers.
Looking at the Return On Equity, with a value of -627.13%, PSTV is doing worse than 79.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -183.84% | ||
| ROE | -627.13% | ||
| ROIC | N/A |
ROA(3y)-132.52%
ROA(5y)-105.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PSTV so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PSTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
PSTV has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PSTV has been increased compared to 5 years ago.
PSTV has a worse debt/assets ratio than last year.
2.2 Solvency
PSTV has an Altman-Z score of -67.53. This is a bad value and indicates that PSTV is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -67.53, PSTV is doing worse than 94.76% of the companies in the same industry.
PSTV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -67.53 |
ROIC/WACCN/A
WACC8.27%
2.3 Liquidity
PSTV has a Current Ratio of 1.26. This is a normal value and indicates that PSTV is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.26, PSTV is not doing good in the industry: 85.02% of the companies in the same industry are doing better.
A Quick Ratio of 1.26 indicates that PSTV should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.26, PSTV is not doing good in the industry: 84.27% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.26 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.56% over the past year.
Looking at the last year, PSTV shows a decrease in Revenue. The Revenue has decreased by -3.49% in the last year.
Measured over the past years, PSTV shows a decrease in Revenue. The Revenue has been decreasing by -3.61% on average per year.
EPS 1Y (TTM)35.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.57%
Revenue 1Y (TTM)-3.49%
Revenue growth 3YN/A
Revenue growth 5Y-3.61%
Sales Q2Q%8.68%
3.2 Future
PSTV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.39% yearly.
Based on estimates for the next years, PSTV will show a very strong growth in Revenue. The Revenue will grow by 86.10% on average per year.
EPS Next Y94.36%
EPS Next 2Y39.33%
EPS Next 3Y24.96%
EPS Next 5Y16.39%
Revenue Next Year15.9%
Revenue Next 2Y8.23%
Revenue Next 3Y60.98%
Revenue Next 5Y86.1%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PSTV. In the last year negative earnings were reported.
Also next year PSTV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PSTV's earnings are expected to grow with 24.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.33%
EPS Next 3Y24.96%
5. Dividend
5.1 Amount
PSTV does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PSTV (11/4/2025, 10:06:45 AM)
0.5115
-0.01 (-1.2%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners1.27%
Inst Owner Change5.35%
Ins Owners0.21%
Ins Owner Change67.22%
Market Cap50.77M
Revenue(TTM)5.32M
Net Income(TTM)-19027000
Analysts82
Price Target8.16 (1495.31%)
Short Float %1.99%
Short Ratio0.09
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-286.82%
Min EPS beat(2)-695.44%
Max EPS beat(2)121.79%
EPS beat(4)3
Avg EPS beat(4)-133.71%
Min EPS beat(4)-695.44%
Max EPS beat(4)121.79%
EPS beat(8)6
Avg EPS beat(8)-58.75%
EPS beat(12)8
Avg EPS beat(12)-40.03%
EPS beat(16)9
Avg EPS beat(16)-31.45%
Revenue beat(2)0
Avg Revenue beat(2)-19.16%
Min Revenue beat(2)-30.01%
Max Revenue beat(2)-8.31%
Revenue beat(4)1
Avg Revenue beat(4)-1.68%
Min Revenue beat(4)-30.01%
Max Revenue beat(4)37.49%
Revenue beat(8)2
Avg Revenue beat(8)-2.41%
Revenue beat(12)3
Avg Revenue beat(12)-6.7%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-9.43%
PT rev (3m)-12.73%
EPS NQ rev (1m)0%
EPS NQ rev (3m)76%
EPS NY rev (1m)73.91%
EPS NY rev (3m)84.81%
Revenue NQ rev (1m)-8.16%
Revenue NQ rev (3m)-17.87%
Revenue NY rev (1m)-14.2%
Revenue NY rev (3m)-3.67%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 9.55 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 16.73 | ||
| P/tB | 22.46 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.03
EYN/A
EPS(NY)-0.13
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0.05
BVpS0.03
TBVpS0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -183.84% | ||
| ROE | -627.13% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-132.52%
ROA(5y)-105.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 5.64% | ||
| Cap/Sales | 0.66% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.26 | ||
| Quick Ratio | 1.26 | ||
| Altman-Z | -67.53 |
F-Score4
WACC8.27%
ROIC/WACCN/A
Cap/Depr(3y)67.77%
Cap/Depr(5y)74.15%
Cap/Sales(3y)82.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)35.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%103.57%
EPS Next Y94.36%
EPS Next 2Y39.33%
EPS Next 3Y24.96%
EPS Next 5Y16.39%
Revenue 1Y (TTM)-3.49%
Revenue growth 3YN/A
Revenue growth 5Y-3.61%
Sales Q2Q%8.68%
Revenue Next Year15.9%
Revenue Next 2Y8.23%
Revenue Next 3Y60.98%
Revenue Next 5Y86.1%
EBIT growth 1Y9.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-11.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.26%
OCF growth 3YN/A
OCF growth 5YN/A
PLUS THERAPEUTICS INC / PSTV FAQ
What is the fundamental rating for PSTV stock?
ChartMill assigns a fundamental rating of 2 / 10 to PSTV.
What is the valuation status for PSTV stock?
ChartMill assigns a valuation rating of 1 / 10 to PLUS THERAPEUTICS INC (PSTV). This can be considered as Overvalued.
Can you provide the profitability details for PLUS THERAPEUTICS INC?
PLUS THERAPEUTICS INC (PSTV) has a profitability rating of 0 / 10.
What is the financial health of PLUS THERAPEUTICS INC (PSTV) stock?
The financial health rating of PLUS THERAPEUTICS INC (PSTV) is 4 / 10.
Is the dividend of PLUS THERAPEUTICS INC sustainable?
The dividend rating of PLUS THERAPEUTICS INC (PSTV) is 0 / 10 and the dividend payout ratio is 0%.